🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/06/2018 | 151,76 | 151,90 | 147,22 | 147,50 | -2,64% | 3,08% | 2.075.400 |
| 26/06/2018 | 154,41 | 155,50 | 151,01 | 151,50 | -2,11% | 2,91% | 1.813.900 |
| 25/06/2018 | 158,72 | 160,17 | 152,91 | 154,76 | -2,78% | 4,57% | 1.491.800 |
| 22/06/2018 | 157,09 | 160,28 | 155,76 | 159,19 | +1,67% | 2,88% | 2.203.500 |
| 21/06/2018 | 157,88 | 157,88 | 155,58 | 156,57 | -0,67% | 1,46% | 835.400 |
| 20/06/2018 | 154,46 | 158,19 | 153,75 | 157,63 | +2,03% | 2,87% | 1.385.400 |
| 19/06/2018 | 150,01 | 155,08 | 149,67 | 154,50 | +1,85% | 3,61% | 1.551.200 |
| 18/06/2018 | 153,90 | 153,97 | 151,41 | 151,69 | -2,15% | 1,66% | 1.371.700 |
| 15/06/2018 | 155,51 | 156,30 | 154,11 | 155,02 | +0,02% | 1,41% | 2.890.200 |
| 14/06/2018 | 152,44 | 155,59 | 152,00 | 154,99 | +2,01% | 2,36% | 1.384.600 |
| 13/06/2018 | 151,11 | 153,39 | 150,53 | 151,94 | +0,63% | 1,89% | 1.307.700 |
| 12/06/2018 | 148,88 | 151,73 | 148,17 | 150,99 | +1,59% | 2,39% | 1.539.700 |
| 11/06/2018 | 150,67 | 151,29 | 147,43 | 148,63 | -1,28% | 2,56% | 1.460.300 |
| 08/06/2018 | 145,98 | 151,26 | 145,98 | 150,55 | +3,29% | 3,62% | 1.791.100 |
| 07/06/2018 | 147,10 | 149,69 | 145,56 | 145,75 | -0,15% | 2,81% | 2.183.200 |
| 06/06/2018 | 145,72 | 146,95 | 144,07 | 145,97 | +0,17% | 1,98% | 3.087.500 |
| 05/06/2018 | 149,71 | 150,40 | 144,14 | 145,72 | -2,63% | 4,18% | 2.957.800 |
| 04/06/2018 | 152,05 | 153,00 | 148,20 | 149,65 | -1,58% | 3,16% | 2.661.000 |
| 01/06/2018 | 154,86 | 154,99 | 150,50 | 152,05 | -1,27% | 2,90% | 2.176.800 |
| 31/05/2018 | 155,49 | 157,07 | 153,52 | 154,00 | -1,69% | 2,28% | 1.649.400 |
| 30/05/2018 | 156,14 | 157,57 | 155,55 | 156,64 | +0,90% | 1,29% | 1.164.400 |
| 29/05/2018 | 156,60 | 157,76 | 153,27 | 155,24 | -1,43% | 2,87% | 1.142.300 |
| 25/05/2018 | 157,00 | 157,90 | 156,22 | 157,50 | +0,34% | 1,07% | 653.600 |
| 24/05/2018 | 156,99 | 157,71 | 155,53 | 156,97 | -0,01% | 1,39% | 634.400 |
| 23/05/2018 | 155,50 | 157,32 | 155,31 | 156,98 | +0,45% | 1,29% | 791.200 |
| 22/05/2018 | 157,10 | 158,22 | 155,80 | 156,28 | +0,04% | 1,54% | 956.400 |
| 21/05/2018 | 157,84 | 158,16 | 155,33 | 156,22 | -0,65% | 1,79% | 1.199.200 |
| 18/05/2018 | 156,61 | 157,52 | 155,33 | 157,24 | +0,58% | 1,40% | 998.500 |
| 17/05/2018 | 156,19 | 157,16 | 155,29 | 156,34 | +0,12% | 1,20% | 1.147.500 |
| 16/05/2018 | 155,79 | 156,45 | 154,40 | 156,16 | +0,40% | 1,32% | 1.240.700 |